Notably, mortality in treated patients who were on MV at baseline was as low as 16.7%, yet only a trend toward significance emerged compared with the SOC group, possibly due to limited sample size.
← all excerpts
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
1
—
—